Aristides Capital’s Janux Therapeutics JANX Stock Holding History

Aristides Capital’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-13,100	Closed	-$181K	–	227
2025 Q4	$181K	Buy	+13,100	New	+$308K	0.03%	208

Other funds holding JANX

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Aristides Capital's JANX Position: Q1 2026 in Review

Aristides Capital sold out of Janux Therapeutics (JANX) in Q1 2026, closing a stake of 13,100 shares — an estimated $181K sold.

Aristides Capital first reported a position in JANX in Q4 2025 and held it in 1 quarter. The position peaked at $181K in Q4 2025. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

Aristides Capital reported no remaining Janux Therapeutics position as of Q1 2026 after selling out during the quarter.
Aristides Capital sold 13,100 Janux Therapeutics shares in Q1 2026, an estimated $181K.
Aristides Capital first reported a position in Janux Therapeutics in Q4 2025 and held it in 1 quarter.
Aristides Capital's Janux Therapeutics position peaked at $181K in Q4 2025.
190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Aristides Capital's 13F filing for Q1 2026, filed 14 May 2026.